DESTINY-Breast04 investigates the use of trastuzumab deruxtecan, in the first randomized clinical trial to show that targeting HER2 provides clinically meaningful benefits for patients with HER2-low metastatic breast cancer (0:10). Dr Judy King (Royal Free Hospital, London, UK) joined touchONCOLOGY to discuss the DESTINY-Breast04 trial results and major highlights in breast cancer presented ASCO 2022. In this interview, Dr King also discusses important data from longer term data presented from DESTINY-Breast03 (1:50), and also the phase 3 TROPiCS-02 trial (03:53), examining sacituzumab govitecan vs physicians’ choice chemotherapy for patients with hormone receptor–positive, HER2-negative advanced breast cancer. Dr King also discusses CDK4/6 trial data (cyclin-dependent kinases 4 and 6) (5:04) and overall survival results, and finally she looks at the phase 2 MAINTAIN study (5:36) which demonstrated the potential benefit of continued CDK 4/6 inhibition with hormone therapy for patients with hormone receptor-positive, HER2-negative metastatic breast cancer who switched endocrine therapy and received the drug after progression on a CDK 4/6 inhibitor.
ASCO 2022 Abstracts discussed in this interview:
- Abstract #LBA3: Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study
- A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.
- Abstract #LBA1001: Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer
Disclosures: Judy King discloses advisory boards membership and speakers fee honoraria from Roche, BMS, Lilly, Novartis, Pfizer, ExactSciences, Prosigna/Veracyte, Eisai and Astra Zeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
Share this Video
Related Videos In Breast Cancer
Matthew Goetz, ESMO 2022: MONARCH 3 trial – Interim overall survival results of abemaciclib + NSAI in patients with HR+, HER2- advanced breast cancer
The MONARCH 3 trial led to abemaciclib plus nonsteroidal aromatase inhibitor approval as initial therapy in postmenopausal patients with hormone receptor-positive (HR+), and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer with significant improvement in progression-free survival. Prof. Matthew Goetz (Mayo Clinic, Rochester, MN, USA) joins touchONCOLOGY to discuss what the MONARCH 3 […]
Sara Tolaney, ESMO 2022: Clinical trial highlights in breast cancer
Dr Sara Tolaney joins touchONCOLOGY to discuss the latest clinical trial highlights in breast cancer, at ESMO 2022. She discusses the overall survival data from the TROPiCS-02 study, investigating sacituzumab govitecan-hziy versus treatment of physician’s choice in participants with HR+/HER2- metastatic breast cancer; and the overall survival data from the phase 3 MONARCH 3 trial, […]
Sara Tolaney, ESMO 2022: AMEERA-3 phase 2 study – Amcenestrant vs. endocrine treatment in patients with endocrine-resistant ER+/HER2− advanced breast cancer
Amcenestrant is an optimized oral selective ER degrader (SERD), which is being investigated in the AMEERA-3 (NCT04059484), an open-label phase II randomized study. In this touchONCOLOGY interview, Dr Sara Tolaney (Dana-Farber Cancer Institute, and Brigham and Women’s Hospital, Boston, MA, USA) discusses the phase II study, investigating amcenestrant versus endocrine treatment of physician’s choice in patients […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!